Home›The Library›Tirzepatide
Tirzepatide
Yes — a genuinely effective, approved medicine with the largest weight-loss effect of any approved obesity drug so far. Like semaglutide, the compounded/grey-market version is not the same legal thing as the branded pen, and that gap is being formally closed.
In brief
Should you care? Yes if you've heard it called "stronger than semaglutide" — the head-to-head trial data on weight loss backs that reputation. The same compounding-restriction story as semaglutide applies here too.The short version
- Dual mechanism: acts on both GIP and GLP-1 receptors, not GLP-1 alone.
- Largest reported effect size of any approved anti-obesity drug in its pivotal trial.
- Compounding pathway closing — same FDA proposal as semaglutide.
What it is
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist — a once-weekly injectable, developed by Eli Lilly.
What the trial evidence shows
SURMOUNT-1 (Jastreboff et al., N Engl J Med 2022, DOI 10.1056/NEJMoa2206038, PMID 35658024) followed 2,539 adults with obesity or overweight, without diabetes, for 72 weeks: mean weight loss ranged 15–20.9% by dose versus 3.1% on placebo — the largest effect size reported for an approved anti-obesity drug at the time. Approved as Mounjaro for type 2 diabetes in May 2022, then as Zepbound for chronic weight management in November 2023. A later trial (Jastreboff et al., N Engl J Med 2024) reported it reduced progression to type 2 diabetes in adults with prediabetes and obesity.
The compounded/grey-market version
Same situation as semaglutide: compounding was permitted during the 2022–2024 shortage (declared resolved December 2024), and FDA's 30 April 2026 proposal to exclude it from the 503B bulks list applies to tirzepatide by name alongside semaglutide and liraglutide (Federal Register 2026-08552).
Not the same as the branded pen
Grey-market vials sold as "tirzepatide" outside a pharmacy-dispensed prescription carry the same legal exposure as unapproved-drug sale, regardless of purity claims.
Safety notes
Gastrointestinal effects dominate the side-effect profile, similar to GLP-1-only drugs but sometimes more pronounced given the added GIP agonism. The class carries the same thyroid C-cell tumor boxed warning as semaglutide, based on rodent data, with the same contraindication for a personal or family history of medullary thyroid carcinoma or MEN2.
References
- Jastreboff et al., "Tirzepatide Once Weekly for the Treatment of Obesity," N Engl J Med 2022;387:205-216, DOI 10.1056/NEJMoa2206038, PMID 35658024.
- FDA, "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List," press release, 30 April 2026; Federal Register 2026-08552.